Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised the lead investor ARCH Venture Partners in Moleculent’s $26 million Series A financing
Mandate

Vinge has advised the lead investor ARCH Venture Partners in Moleculent’s $26 million Series A financing

June 19, 2024

Moleculent AB, a company pioneering technology to study the communication between cells in human tissue, has closed its oversubscribed $26 million Series A financing. The round was led by ARCH Venture Partners and co-led by Eir Ventures with participation from the company’s existing investors.

ARCH Venture Partners creates and invests in groundbreaking life science and technology companies. The firm is a recognized leader in commercializing technologies developed at academic institutions, corporate research groups and national laboratories.

The Vinge team primarily consisted of Johan Larsson, Maria Dahlin Kolvik, Stojan Arnerstål, David Olander, Johan Gavelin, Olof Löfvenberg and Alice Göransson.

Related

Vinge advises ABGSC in connection with EQL Pharma’s inaugural bond issuance

 Vinge has advised ABG Sundal Collier in connection with EQL Pharma AB (publ)’s ( “EQL”) inaugural issuance of SEK 350,000,000 senior secured bonds within a framework of up to SEK 700,000.
January 24, 2025

Vinge advises the majority shareholders Altor, Telia Company, Time For Growth and Zenith VC in the divestment of shares in Marshall Group

 Vinge advises the majority shareholders Altor, Telia Company, Time For Growth and Zenith VC in connection with the divestment of shares in Marshall Group AB (publ) (”Marshall Group”) to HongShan Group, formerly known as Sequoia China. The Marshall Family will continue as owner in the Marshall Group.
January 24, 2025

Vinge represents Sedana Medical AB in the acquisition of Innovatif Cekal

 Vinge has represented Sedana Medical AB (publ) in connection with the acquisition of Innovatif Cekal. Innovatif Cekal, based in Klang near Kuala Lumpur, Malaysia, is a manufacturer of medical devices. This acquisition enhances Sedana Medical's control over its supply chain and improves profitability through reduced cost of goods.
January 22, 2025